Skip to main content
Erschienen in: Critical Care 1/2020

Open Access 01.12.2020 | Research Letter

International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe

verfasst von: Karin Thevissen, Cato Jacobs, Michelle Holtappels, Mitsuru Toda, Paul Verweij, Joost Wauters

Erschienen in: Critical Care | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Karin Thevissen and Cato Jacobs are shared first authors.
A correction to this article is available online at https://​doi.​org/​10.​1186/​s13054-020-02901-x.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
IAPA
Influenza-associated pulmonary aspergillosis
IPA
Invasive pulmonary aspergillosis
GM
Galactomannan
BAL
Broncho-alveolar lavage
ELSO
Extracorporeal Life Support Organization
SCCM
Society of Critical Care Medicine
ESICM
European Society of Intensive Medicine
US
United States
ICU
Intensive care unit
Dear Editor,
Historically, fungal infections have not been considered an important influenza complication. In 2018, a retrospective multicenter cohort study in Belgium and the Netherlands identified aspergillosis in 19% of patients with severe influenza. As influenza seemed independently associated with IPA, the term influenza-associated pulmonary aspergillosis (IAPA) was introduced [1, 2]. In contrast, a single-center retrospective Canadian study reported an incidence of 7.2% [3]. Incidence seemingly varies between geographical regions and centers, but awareness among physicians may also vary. Diagnosis of IAPA is still challenging. Since culture has low sensitivity, non-culture-based diagnostic methods like galactomannan (GM) should be used [4].
As no data exist on IAPA awareness in different parts of the world, nor on differences in clinical use of GM in broncho-alveolar lavage (BAL) or serum in critically ill influenza patients, we designed a simple survey (Table 1) and invited 20,093 members of the ELSO, SCCM, and ESICM to participate. A total of 565 responses were received, of which 90% from critical care physicians. Notably, 40% respondents were based in the US, 37% in Europe, and 22% in other continents (Fig. 1a).
Table 1
Overview of respondent’s input based on the survey
 
Responses
Total
Europe
U.S.
Othera
Valid respondents
565 (100%)
208 (37%)
224 (40%)
133 (23%)
Role at ICU
 Critical care physician
509/565 (90%)
197/208 (95%)
186/224 (83%)
126/133 (95%)
 Infectious diseases physician
8/565 (1%)
4/208 (2%)
3/224 (1%)
1/133 (0.5%)
 Nurse
9/565 (2%)
1/208 (1%)
7/224 (3%)
1/133 (0.5%)
 Other
39/565 (7%)
6/208 (2%)
28/224 (13%)
5/133 (4%)
Number of ICU beds
 < 20 beds
176/554 (32%)
94/207 (46%)
27/222 (12%)
55/125 (44%)
 21–60 beds
226/554 (41%)
85/207 (41%)
89/222 (40%)
52/125 (42%)
 61–100 beds
68/554 (12%)
17/207 (8%)
43/222 (19%)
8/125 (6%)
 > 100 beds
84/554 (15%)
11/207 (5%)
63/222 (29%)
10/125 (8%)
Number of severe influenza cases per season
 < 10 cases
132/557 (23%)
56/206 (27%)
32/222 (14%)
44/129 (34%)
 11–30 cases
272/557 (49%)
118/206 (57%)
99/222 (45%)
55/129 (43%)
 31–50 cases
60/557 (11%)
18/206 (9%)
30/222 (14%)
12/129 (9%)
 >  50 cases
49/557 (9%)
10/206 (5%)
27/222 (12%)
12/129 (9%)
 I do not know
44/557 (8%)
4/206 (2%)
34/222 (15%)
6/129 (5%)
NAIs as standardized treatment
 Yes
416/556 (75%)
162/206 (79%)
165/222 (74%)
89/128 (70%)
 Yes, but only if influenza symptoms started ≤ 48–72 h before ICU admission
97/556 (17%)
34/206 (17%)
41/222 (19%)
22/128 (17%)
 No
27/556 (5%)
7/206 (3%)
3/222 (1%)
17/128 (13%)
 I do not know
16/556 (3%)
3/206 (1%)
13/222 (6%)
0
Obtaining lower respiratory samples
 Always
78/554 (14%)
52/205 (25%)
10/220 (5%)
16/129 (12%)
 Very often
139/554 (25%)
67/205 (33%)
43/220 (19%)
29/129 (22%)
 Sometimes
187/554 (34%)
50/205 (24%)
97/220 (44%)
40/129 (31%)
 Rarely
129/554 (23%)
31/205 (15%)
65/220 (29%)
33/129 (26%)
 Never
16/554 (3%)
5/205 (3%)
1/220 (1%)
10/129 (8%)
 N/A—have not treated patients
5/554 (1%)
0
4/220 (2%)
1/129 (1%)
Galactomannan testing in BAL
 Always
52/551 (9%)
38/204 (19%)
5/220 (2%)
9/127 (7%)
 Very often
65/551 (12%)
38/204 (19%)
14/220 (6%)
13/127 (10%)
 Sometimes
107/551 (19%)
37/204 (18%)
46/220 (21%)
24/127 (19%)
 Rarely
163/551 (30%)
43/204 (21%)
83/220 (38%)
37/127 (29%)
 Never
143/551 (26%)
44/204 (21%)
61/220 (28%)
38/127 (30%)
 N/A—have not treated patients
21/551 (4%)
4/204 (2%)
11/220 (5%)
6/127 (5%)
Galactomannan testing in serum
 Always
39/554 (7%)
28/205 (14%)
5/220 (2%)
6/129 (5%)
 Very often
60/554 (11%)
36/205 (18%)
11/220 (5%)
13/129 (10%)
 Sometimes
115/554 (21%)
42/205 (20%)
46/220 (21%)
27/129 (21%)
 Rarely
175/554 (31%)
47/205 (23%)
94/220 (43%)
34/129 (26%)
 Never
142/554 (26%)
48/205 (23%)
51/220 (23%)
43/129 (33%)
 N/A—have not treated patients
23/554 (4%)
4/205 (2%)
13/220 (6%)
6/129 (5%)
Number of IAPA in influenza patients in the past 5 years
 No
347/553 (63%)
85/204 (41%)
183/220 (83%)
79/129 (61%)
 Yes, 1 patient
77/553 (14%)
34/204 (17%)
21/220 (9%)
22/129 (17%)
 Yes, 2–5 patients
99/553 (18%)
61/204 (30%)
15/220 (7%)
23/129 (18%)
 Yes, > 5 patients
30/553 (5%)
24/204 (12%)
1/220 (1%)
5/129 (4%)
Descriptive statistics were used to analyze the differences in proportions of responses between Europe, the US, and other countries. Fisher’s exact or χ2 test was used to calculate the p values. Correction for multiple comparisons was applied. The Spearman rank-order correlation coefficient was used to determine univariate correlations between parameters. A p value of < 0.05 was considered statistically significant. Results were analyzed using SPSS (IBM SPSS Statistics version 26). ICU intensive care unit, N/A not applicable, BAL bronchoalveolar lavage, IAPA influenza-associated pulmonary aspergillosis
aOther countries + unknown
The majority (72%, n = 404) of respondents reported up to 30 severe influenza cases per season. Globally, 63% (n = 347) of respondents had never heard of or seen IAPA in the past 5 years. In contrast to the US (17%, n = 37) and other countries (39%, n = 50), a majority of European participants (58%, n = 119) was familiar with IAPA.
Less than half of respondents (39%, n = 217) indicated frequent sampling of lower respiratory specimens, whereas 26% (n = 145) rarely or never performed sampling. We observed differences across different countries: European respondents performed lower respiratory sampling very often or always (58%, n = 119). This was more than the respondents in the US (24%, n = 53; p < 0.001) or those in other countries (33%, n = 45; p < 0.001).
While 39% of respondents did take lower respiratory samples, the majority of respondents (79%, n = 434) seldom determined GM in BAL. In general, GM determination in BAL/serum was more frequently reported by respondents in Europe than in the US (p < 0.01) or other countries (p < 0.01). Interestingly, both GM determination in BAL and serum correlated with the reported number of IAPA cases in all regions. Based on the calculated mean of response histograms, a web diagram was constructed, showing that a higher number of observed IAPA cases were associated with more intensive sampling (Fig. 1b).
Our results show that differences exist in awareness and diagnostic practices related to IAPA among surveyed ICU clinicians in Europe, the US, and other countries. Moreover, many clinicians were unaware of the association between influenza and aspergillosis, with European respondents having seen or heard more frequently of IAPA cases than those in the US and other countries. Although the observed differences in IAPA cases could be explained by true variation in IAPA prevalence (e.g., due to differences in environmental/genetic factors, influenza vaccination coverage, use of antiviral therapy or steroids [5, 6]), the condition might be underdiagnosed outside Europe, which is supported by lower use of GM testing on BAL or serum. Of course, these findings might not necessarily be generalizable due to the low response rate (3%). Actually, the questions were deliberately kept simple and straightforward to increase the response rate. Anyway, greater awareness of IAPA is needed as are rapid diagnostic tests. Based on the conclusions of this survey, it is clear that more multicentric prospective studies are needed to assess the incidence and risk factors for IAPA in different parts of the world, thereby taking the most updated guidelines on diagnostic and sampling practices into account, as well as the use of steroids and the consensus definitions regarding fungal infection versus colonization.

Acknowledgements

Not applicable.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC.
Not applicable
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza. Curr Opin Infect Dis. 2018;31:471–80. Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe influenza. Curr Opin Infect Dis. 2018;31:471–80.
2.
Zurück zum Zitat Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–92. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–92.
4.
Zurück zum Zitat Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid. Am J Respir Crit Care Med. 2008;177:27–34. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, et al. Galactomannan in bronchoalveolar lavage fluid. Am J Respir Crit Care Med. 2008;177:27–34.
5.
Zurück zum Zitat Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. Nat Rev Dis Prim. 2018;4:1–21. Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, et al. Influenza. Nat Rev Dis Prim. 2018;4:1–21.
6.
Zurück zum Zitat Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68:895–902. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68:895–902.
Metadaten
Titel
International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe
verfasst von
Karin Thevissen
Cato Jacobs
Michelle Holtappels
Mitsuru Toda
Paul Verweij
Joost Wauters
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2020
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-2808-8

Weitere Artikel der Ausgabe 1/2020

Critical Care 1/2020 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.